DexCom (DXCM) shares are soaring 5.02% in pre-market trading on Monday, despite recent price target reductions from multiple analysts. The medical device company, known for its continuous glucose monitoring systems, is showing resilience in the face of adjusted Wall Street expectations.

Barclays maintained its Equal-Weight rating on DexCom but lowered its price target to $80 from $98. Similarly, Truist Securities reduced its target to $82 from $94, while reiterating a Buy rating on the stock. These adjustments come in the wake of DexCom's recent Q3 earnings report, which appears to have prompted a reassessment of the company's near-term prospects.

The stock's strong performance, despite the lowered price targets, suggests that investors remain optimistic about DexCom's long-term potential. This could be attributed to Truist's maintained Buy rating, indicating continued confidence in the company's growth trajectory. Additionally, the revised price targets still represent a significant upside from current trading levels, potentially encouraging investors to view the stock as undervalued at its current price.